Lightlake Therapeutics Inc. (OTC.BB.-LLTP), the specialist biopharma company, is extending the range of its research into effective treatments for eating disorders to bulimia and amphetamine, cocaine and opioid painkiller dependencies, for which it holds existing US and European patents.

The company will shortly be commencing trials on its bulimia treatment and is currently carrying out a Phase II trial for its proprietary treatment for obese and overweight patients with Binge Eating Disorder.

Lightlake has developed a unique opioid antagonist nasal spray, and is applying its technology and expertise to develop other pharmacy based health delivery programmes

Dr. Michael Sinclair, the Chairman of Lightlake Therapeutics stated:-

"Whilst Lightlake Therapeutics' primary focus is to investigate the use of our opioid antagonist nasal spray for obese and overweight patients with Binge Eating Disorder, our research suggests our proprietary technology can be extended to treat other conditions including drug dependency, overdose, and Bulimia Nervosa.

Opioid antagonists are very safe compounds and have been used for over 30 years with proven efficacy for intra-nasal delivery with minimal side effects. The treatment programmes we are developing mean that the nasal spray is likely to be used by patients only when they are about to undertake behaviour they wish to extinguish.

Dr. David Sinclair, Lightlake's Chief Scientific Officer, is a pioneer and one of the world's leading experts in the field of opioid antagonists. His acclaimed Sinclair Method for the treatment of alcoholism has been the subject of over 80 multi-centre clinical trials with exceptional results.

The physiological mechanism for treating eating disorders and drug dependency is identical and we confidently expect the results of the Phase II Binge Eating Disorder trial to be as successful as David Sinclair's results in treating alcoholism.

The growth in importance in Pharmacy based health care delivery programmes is notable throughout the developed world. We have reached an agreement with Celesio, Europe's leading pharmacy distribution network, with 65,000 associate outlets in Europe, to develop a pharmacy based Binge Eating Disorder treatment programme using Lightlake's proprietary product. We aim to extend this community based arrangement to other emerging markets.

With US and European Government predictions that over 40% of their citizens will be clinically obese by 2020, the market for Lightlake's products worldwide is considerable. Conservative estimates are that 30% of obese and overweight individuals exhibit binge eating behaviour. Lightlake's estimate of the market for its product in the US alone is 20million individuals. We anticipate similar sized markets in Central and South America; Europe; India and South East Asia.

We aim to deliver treatments that cost consumers less than US $12 per week which is comparable to other products on the market."

Source:
Lightlake Therapeutics, Inc.